country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-108002

Copy Link Print Information

A 33903

A 33903 is a respiratory syncytial virus (RSV) replication inhibitor. A 33903 can be used for the research of RSV-infection.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

CAS No.: 70890-53-8
Formule: C₁₇H₁₅N₃O₂
Masse moléculaire:293.32

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (273 KB)

A 33903 Chemical Structure

CAS No.: 70890-53-8

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
Chemical Information
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

A 33903 is a respiratory syncytial virus (RSV) replication inhibitor. A 33903 can be used for the research of RSV-infection^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
HEp-2	CC₅₀	>50 μM Compound: A-33903	Cytotoxicity against RSV RSS infected human Hep2 cells after 6 days by XTT assay Cytotoxicity against RSV RSS infected human Hep2 cells after 6 days by XTT assay	[PMID: 17576833]
HEp-2	EC₅₀	>100 μM Compound: A-33903	Antiviral activity against plaque picked RSV604-resistant RSV RSS from passage 2 in human Hep2 cells by plaque reduction assay Antiviral activity against plaque picked RSV604-resistant RSV RSS from passage 2 in human Hep2 cells by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	10.1 μM Compound: A-33903	Antiviral activity against RSV RSS infected human Hep2 cells assessed as reduction of viral antigen synthesis after 3 days by ELISA Antiviral activity against RSV RSS infected human Hep2 cells assessed as reduction of viral antigen synthesis after 3 days by ELISA	[PMID: 17576833]
HEp-2	EC₅₀	15.1 μM Compound: A-33903	Antiviral activity against RSV A2 infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV A2 infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	27.6 μM Compound: A-33903	Antiviral activity against plaque picked A-33903-resistant RSV RSS from passage 2 in human Hep2 cells by plaque reduction assay Antiviral activity against plaque picked A-33903-resistant RSV RSS from passage 2 in human Hep2 cells by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	3.5 μM Compound: A-33903	Antiviral activity against RSV B infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV B infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	7.2 μM Compound: A-33903	Antiviral activity against RSV Long infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV Long infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	8.1 μM Compound: A-33903	Antiviral activity against DMSO-passaged wild type RSV RSS infected human Hep2 cells by plaque reduction assay Antiviral activity against DMSO-passaged wild type RSV RSS infected human Hep2 cells by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	9.6 μM Compound: A-33903	Antiviral activity against RSV RSS infected human Hep2 cells assessed as inhibition of virus-induced cell death after 6 days by XTT assay Antiviral activity against RSV RSS infected human Hep2 cells assessed as inhibition of virus-induced cell death after 6 days by XTT assay	[PMID: 17576833]
HEp-2	EC₅₀	9.7 μM Compound: A-33903	Antiviral activity against RSV RSS infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV RSS infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	IC₅₀	17.6 μM Compound: 18	Antiviral activity against RSV Long in Hep2 cells by ELISA Antiviral activity against RSV Long in Hep2 cells by ELISA	[PMID: 16570927]
HEp-2	IC₅₀	17.8 μM Compound: 18	Antiviral activity against RSV B in Hep2 cells by ELISA Antiviral activity against RSV B in Hep2 cells by ELISA	[PMID: 16570927]
HEp-2	IC₅₀	3.6 μM Compound: 18	Antiviral activity against RSV B in Hep2 cells by plaque assay Antiviral activity against RSV B in Hep2 cells by plaque assay	[PMID: 16570927]
HEp-2	IC₅₀	7.1 μM Compound: 18	Antiviral activity against RSV RSS in Hep2 cells by plaque assay Antiviral activity against RSV RSS in Hep2 cells by plaque assay	[PMID: 16570927]
HEp-2	IC₅₀	7.2 μM Compound: 18	Antiviral activity against RSV Long in Hep2 cells by plaque assay Antiviral activity against RSV Long in Hep2 cells by plaque assay	[PMID: 16570927]
HEp-2	IC₅₀	8.6 μM Compound: 18	Antiviral activity against RSV RSS in Hep2 cells by whole cell XTT assay Antiviral activity against RSV RSS in Hep2 cells by whole cell XTT assay	[PMID: 16570927]
HEp-2	IC₅₀	9.3 μM Compound: 18	Antiviral activity against RSV RSS in Hep2 cells by ELISA Antiviral activity against RSV RSS in Hep2 cells by ELISA	[PMID: 16570927]
Sf9	IC₅₀	>10 μM Compound: figure 3, R4C2	Displacement of [3H]Ro15-4513 from GABAA alpha-1-beta-2-gamma-2 receptor expressed in Sf9 baculovirus system Displacement of [3H]Ro15-4513 from GABAA alpha-1-beta-2-gamma-2 receptor expressed in Sf9 baculovirus system	[PMID: 18537233]
Sf9	IC₅₀	>10 μM Compound: figure 3, R4C2	Displacement of [3H]Ro15-4513 from GABAA alpha-5-beta-2-gamma-2 receptor expressed in Sf9 baculovirus system Displacement of [3H]Ro15-4513 from GABAA alpha-5-beta-2-gamma-2 receptor expressed in Sf9 baculovirus system	[PMID: 18537233]

Chemical Information

CAS No. 70890-53-8
Masse moléculaire 293.32
Formule C₁₇H₁₅N₃O₂
SMILES

O=C(C)NC1N=C(C2=C(NC1=O)C=CC=C2)C3=CC=CC=C3
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (273 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Chapman J, et al. RSV604, a novel inhibitor of respiratory syncytial virus replication[J]. Antimicrobial agents and chemotherapy, 2007, 51(9): 3346-3353. [Content Brief]

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

100 mg

Obtenir un devis En stock